| Literature DB >> 18507835 |
Jon S Blevins1, Kayla E Hagman, Michael V Norgard.
Abstract
BACKGROUND: Decorin-binding proteins (Dbps) A and B of Borrelia burgdorferi, the agent of Lyme disease, are surface-exposed lipoproteins that presumably bind to the extracellular matrix proteoglycan, decorin. B. burgdorferi infects various tissues including the bladder, heart, joints, skin and the central nervous system, and the ability of B. burgdorferi to bind decorin has been hypothesized to be important for this disseminatory pathogenic strategy.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18507835 PMCID: PMC2430964 DOI: 10.1186/1471-2180-8-82
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Construction of . (A) Strategy for the replacement of the dbpBA operon with the PflgB-kan and complementation with pKH2000. pKHdbpBAko was the pGEM-T easy-based suicide plasmid used to transform Bb297 for the homologous recombination of the kanamycin-resistance gene into the dbpBA operon. "A" denotes AscI sites. PflgB-kan denotes the kanamycin-resistance marker expressed from the flgB promoter. The borrelial shuttle vector containing the dbpBA Prom fused to the dbpA ORF (pKH2000) was transformed into BbKH500 to restore DbpA expression. Oligonucleotide primers used for PCR are indicated with short arrows. (B) PCR using primers ko5 and ko4 (shown in panel A). The first two lanes are undigested PCR products from Bb297 and BbKH500, whereas the second two lanes are the corresponding PCR products digested with AscI. (C) Lanes 1, 3 and 5 are PCR products derived from BbKH500 template DNA and lanes 2, 4 and 6 are PCR products derived from Bb297 template DNA. Primer pairs used in PCR are indicated above the lanes. FlaB5' and FlaB3' primers amplify flaB of B. burgdorferi. DNA size standards (M) are shown in base pairs on the left.
Figure 2PCR-based plasmid profiling to compare the plasmid contents of the strains employed in this study. PCR amplification with primers specific for each of the known endogenous B. burgdorferi plasmids was used to compare the plasmid content of parent Bb297, BbKH500, and BbKH501. Sequence information for the primers utilized is provided in Table 4. Plasmid designations above each lane are based on strain B31 plasmid annotation. DNA size standards (M) are shown in base pairs.
Figure 3Characterization of BbKH500 and BbKH501. (A) Whole-cell lysates of Bb297, BbKH500, and BbKH501 were resolved by SDS-PAGE (12.5% acrylamide) and stained with Coomassie brilliant blue or (B) or transferred to nitrocellulose and assessed by immunoblot analysis with antibodies as noted on the right. (C) PCR analysis of Bb297, BbKH500 and BbKH501 for presence of dbpA. (D) Immunoblot analysis of whole-cell lysates of proteinase K-digested (+) or undigested (-) Bb297 or BbKH501. Antibodies used noted on the right. Molecular mass of markers (M) in panel A are shown in kDa. The arrow at the right in panel A denotes the protein band corresponding to DbpA. DNA size standards (M) in panel C are shown in base pairs.
Assessing infectivity of BbKH500 in needle-challenged C3H/HeJ mice.
| Inoculation dose (bacteria/inoculation) | ||||
| Time post-infection (wks) | 104a | 105a | 106a | 107a |
| 5 | 0/10 | 0/17 | 0/10 | 5/5 |
| 10 | ND | 3/17 | 2/10 | ND |
| 14b | 0/5 | 2/10 | 4/10 | 5/5 |
| Cumulative results | 0/15 | 5/27 | 6/20 | 10/10 |
a Mice were needle infected with varying concentrations of bacteria. Infection rates were assessed at the noted timepoints by culturing BbKH500 from ear-punch biopsies.
b Mice from 14 week timepoint represent groups distinct from the 5- and 10-week groups.
Assessing infectivity of BbKH500 via tick inoculation of C3H/HeJ mice
| Strain | Ticks/mousea | Mouse infectivityb |
| Bb297 | 5 | 2/2 |
| BbKH500 | 5 | 1/2 |
| 10 | 4/6 |
a Varying number of ticks infected with BbKH500 were allowed to feed to repletion on naïve mice.
b Infection rates were assessed at three weeks post-infestation by culturing BbKH500 from ear-punch biopsies
Oligonucleotide primers used for cloning and PCR confirmation.
| Designation | Sequence |
| ko1 | GGATCTTAAGAATTTCAAATTTT |
| ko2 | TATA |
| ko3 | TATA |
| ko4 | TTTAGATTCTAAAGTTTAGATAAAAATTGGTCGGG |
| ko5 | AAACAAGTCTTAAAATCACAAGC |
| kan5' | AGCCATATTCAACGGGAAACG |
| kan3' | TTCATATCAGGATTATCAATACC |
| vlsE-5' | GATGCAGAGAAGGCTGCTGCTGCAGTTAGTGC |
| vlsE-3' | TATAAGCTTTCATCAGAGAGTCTTATTAACAGCAGTCTCAAC |
| BBE22-5' | AAATTAATTTCTTTGATCAACCAAC |
| BBE22-3' | TATATTAAGCTTACTTTGGCTGTCG |
| FlaB5' | ATGATTATCAATCATAATACATCAGCTATTAA |
| FlaB3' | TTATCTAAGCAATGACAAAACATATTGGGGAA |
| comp1 | GGCTTCTCTTTTATTTTTAAGACC |
| comp2 | |
| comp3 | AGATCT |
| comp4 | |
| comp5 | GTAGCTCCACTTTTGCTTC |
a AscI site underlined.
b NdeI site underlined.
c SphI site underlined
Oligonucleotide primers used for plasmid profiling.
| Primer | Sequence | Reference |
| lp54 5' | ATGAGCAAAAAAGTAATTTTAATAT | [55] |
| lp54 3' | CACTAATTCTTTTTGAATTACTAAT | [55] |
| cp26 5' | ATGCCTCCAAAAGTGAAGATAAAAA | [55] |
| cp26 3' | TAGCTTATAATTAAAAATTATTGAT | [55] |
| cp9 5' | ATGCAAAAAATAAACATAGCTAAAT | [55] |
| cp9 3' | ATCTTCTTCAAGATATTTTATTATA | [55] |
| lp17 5' | GTGTATACTGACCCAAGGTCAATTA | [55] |
| lp17 3' | CAATAATGTGATATTTTTAAGAAAT | [55] |
| lp25 5' | AAATTAATTTCTTTGATCAACCAAC | This study |
| lp25 3' | TATATTAAGCTTACTTTGGCTGTCG | This study |
| lp28-1 5' | GATGCAGAGAAGGCTGCTGCTGCAGTTAGTGC | This study |
| lp28-1 3' | TATAAGCTTTCATCAGAGAGTCTTATTAACAGCAGTCTCAAC | This study |
| lp28-2 5' | ATGGCGCTGATTACATTAATTGTCG | [55] |
| lp28-2 3' | AATCTTGAAGAACCTTGCATCTTTA | [55] |
| lp28-3 5' | CTGAAAATGAAGGAGAAGCGGGTGG | [55] |
| lp28-3 3' | TAGGCTAATACCAATTCGTACAAAT | [55] |
| lp28-4 5' | ATGAAATGCCATATAATTGCAACTA | [55] |
| lp28-4 3' | AATCCGACAGATCTGGTTTGTCCAG | [55] |
| lp38 5' | ATGATTATTACCCAAACAACGCCC | This study |
| lp38 3' | TTTTAAATCCATTTTCACAATATG | This study |
| lp36 5' | TTCTTATCCCTGACTTTCACTTTTGAGG | This study |
| lp36 3' | TCCTTTACTTCTATGTTTTTACTTTCCTTGGT | This study |
| lp5 5' | ATGAATGGAATAATTAACGATACAC | [55] |
| lp5 3' | AATATTAGGATGAAGATTATAAATT | [55] |
| lp21 5' | TGTGGTTGCTAAAACCCAAGCGT | This study |
| lp21 3' | TTGTTTCTAATTGCTCTGAATTGCATCC | This study |
| Chrom 5' | GATTATCAATCATAATACATCAGC | [55] |
| Chrom 3' | TCTAAGCAATGACAAACATATTGG | [55] |
| cp18-1 5' | AGGGGAATGTATTAATTGATAATTCA | This study |
| cp18-1 3' | AGATTTTTTCAAAACATTTGGCGAT | This study |
| cp18-2 5' | TCAGAAAGCATACCATTACAAGACAAC | This study |
| cp18-2 3' | AATAATACCTTTTTCTACGCCCGATA | This study |
| cp32-1 5' | GTTATAATACCTATTCAAGCAGAAAGG | This study |
| cp32-1 3' | GCTCCCTTCTAATACTTTTCTATAA | This study |
| cp32-2 5' | CAAGCGAGTTTATTCCCCTTAAA | This study |
| cp32-2 3' | ATTCTAATATTGTCCACTTTATGAAAT | This study |
| cp32-3 5' | ACTTGCAAGAGCACAGGTCTATAATTA | This study |
| cp32-3 3' | CTTAATACAATTAACGTTTCCAGTATA | This study |
| cp32-4 5' | GTATAAATGCTTTTGGTTATAAGCACAC | This study |
| cp32-4 3' | GAAACTCCTTCTCTAACCTTTACATAC | This study |
| cp32-5 5' | GCCTTATAAGGAACATAGGTTAAAGG | This study |
| cp32-5 3' | AGATTTCAAGCGCTCCTTCAACAAA | This study |
| cp32-6 5' | GGTGCTTTAGACACAAGAGATGTG | This study |
| cp32-6 3' | GAACAAATTTCAGATTTAACATTTATCG | This study |
| cp32-7 5' | GTCAAATTTAAGCTGTTTTAGCAGTG | This study |
| cp32-7 3' | TATTTACTAATCTATTTTTCAATTTTTCA | This study |